| P2093 | author name string | Pierre Lestage | |
| | David Guez | |
| | Guillaume De Nanteuil | |
| | Roeline Jochemsen | |
| | Pierre-Alain Boyer | |
| | Philippe Morain | |
| | Jean-Loïc Robin | |
| P2860 | cites work | S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. | Q33859153 |
| | Fronto-striatal cognitive deficits at different stages of Parkinson's disease | Q34296796 |
| | Visuospatial memory deficits at different stages of Parkinson's disease | Q34354414 |
| | Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease | Q34374332 |
| | Pharmacodynamic and pharmacokinetic profile of S 17092, a new orally active prolyl endopeptidase inhibitor, in elderly healthy volunteers. A phase I study | Q36055312 |
| | Neuropeptides and Alzheimer's disease | Q37948072 |
| | Axonal regeneration, growth factors and neuropeptides | Q38179476 |
| | Evidence for a decrease in substance P content of substantia nigra in Huntington's chorea | Q39130542 |
| | Prolyl endopeptidase | Q40164039 |
| | The role of neuropeptides in learning: focus on the neurokinin substance P. | Q40400806 |
| | Recovery from unilateral 6-hydroxydopamine lesion of substantia nigra promoted by the neurotachykinin substance P 1-11. | Q41092780 |
| | 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa | Q41437567 |
| | Effect of neuropeptides on cognitive function. | Q41604656 |
| | Central injection of substance P elicits grooming behavior and motor inhibition in mice | Q41702058 |
| | TRH attenuates scopolamine-induced memory impairment in humans | Q41897125 |
| | Effect of thyrotropin releasing hormone (TRH) on acetylcholine release from different brain areas investigated by microdialysis | Q42084295 |
| | New prolyl endopeptidase inhibitors: in vitro and in vivo activities of azabicyclo[2.2.2]octane, azabicyclo[2.2.1]heptane, and perhydroindole derivatives | Q42555567 |
| | Substance P-like immunoreactivity is reduced in Alzheimer's disease cerebral cortex | Q43480542 |
| | L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction | Q43643543 |
| | Effects of the prolyl endopeptidase inhibitor S 17092 on cognitive deficits in chronic low dose MPTP-treated monkeys | Q43854204 |
| | Behavioural effects of selective tachykinin agonists in midbrain dopamine regions | Q44316951 |
| | Substance P-like immunoreactive neurons are depleted in Alzheimer's disease cerebral cortex | Q44800050 |
| | Essential role of neocortical acetylcholine in spatial memory | Q46181651 |
| | Knowing which and knowing what: a potential mouse model for age-related human declarative memory decline | Q48098564 |
| | Delayed matching-to-sample, object retrieval, and discrimination reversal deficits in chronic low dose MPTP-treated monkeys | Q48250417 |
| | A triple dissociation of memory systems: hippocampus, amygdala, and dorsal striatum | Q48336730 |
| | Involvement of nicotinergic mechanisms in thyrotropin-releasing hormone-induced neurologic recovery after concussive head injury in the mouse | Q48362552 |
| | Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients | Q48397902 |
| | Neuropeptides and dementia. | Q48404814 |
| | Substance P raises neuronal membrane excitability by reducing inward rectification | Q48479845 |
| | Neuropeptides in Alzheimer type dementia | Q48712331 |
| | Effect of Org2766, an ACTH(4–9) analogue, on recovery after bilateral transection of the fimbria fornix in the rat | Q48764968 |
| | Cognitive deficits in the early stages of Parkinson's disease | Q48800336 |
| | Modulation of cortical acetylcholine release by serotonin: the role of substance P interneurons | Q48875017 |
| | Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys | Q48951590 |
| | Age-related changes in central nervous system enkephalins and substance P | Q49155003 |
| | The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers. | Q52091302 |
| | Cognitive impairments associated with early Parkinson's disease. | Q52116212 |
| | Septal vasopressin modulates social memory in male rats. | Q52122344 |
| | Neuropeptide substance P improves water maze performance in aged rats | Q52243839 |
| | Decrease of substance P-like immunoreactivity in the substantia nigra and pallidum of parkinsonian brains | Q64765365 |
| | Grooming behavior induced by substance P | Q69055525 |
| | Trophic effect of various neuropeptides on the cultured ventral spinal cord of rat embryo | Q69096610 |
| | A peptide enhancement strategy in Alzheimer's disease: pilot study with TRH-physostigmine infusions | Q70482095 |
| | Neurotrophic effects of substance P on hippocampal neurons in vitro | Q71617972 |
| | A survey of substance P, somatostatin, and neurotensin levels in aging in the rat and human central nervous system | Q72660489 |
| | Age-related changes in the contents of neuropeptides in the rat brain and pituitary | Q72743921 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 31-52 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | CNS Neuroscience & Therapeutics | Q5013184 |
| P1476 | title | S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies | |
| P478 | volume | 8 | |